nach oben

European Archives of Psychiatry and Clinical Neuroscience

Erschienen in:

29.12.2016 | Original Paper

Insulin-regulated aminopeptidase immunoreactivity is abundantly present in human hypothalamus and posterior pituitary gland, with reduced expression in paraventricular and suprachiasmatic neurons in chronic schizophrenia

verfasst von: Hans-Gert Bernstein, Susan Müller, Hendrik Dobrowolny, Carmen Wolke, Uwe Lendeckel, Alicja Bukowska, Gerburg Keilhoff, Axel Becker, Kurt Trübner, Johann Steiner, Bernhard Bogerts

Erschienen in: European Archives of Psychiatry and Clinical Neuroscience | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

The vasopressin- and oxytocin-degrading enzyme insulin-regulated aminopeptidase (IRAP) is expressed in various organs including the brain. However, knowledge about its presence in human hypothalamus is fragmentary. Functionally, for a number of reasons (genetic linkage, hydrolysis of oxytocin and vasopressin, its role as angiotensin IV receptor in learning and memory and others) IRAP might play a role in schizophrenia. We studied the regional and cellular localization of IRAP in normal human brain with special emphasis on the hypothalamus and determined numerical densities of IRAP-expressing cells in the paraventricular, supraoptic and suprachiasmatic nuclei in schizophrenia patients and controls. By using immunohistochemistry and Western blot analysis, IRAP was immunolocalized in postmortem human brains. Cell countings were performed to estimate numbers and numerical densities of IRAP immunoreactive hypothalamic neurons in schizophrenia patients and control cases. Shape, size and regional distribution of IRAP-expressing cells, as well the lack of co-localization with the glia marker glutamine synthetase, show that IRAP is expressed in neurons. IRAP immunoreactive cells were observed in the hippocampal formation, cerebral cortex, thalamus, amygdala and, abundantly, hypothalamus. Double labeling experiments (IRAP and oxytocin/neurophysin 1, IRAP with vasopressin/neurophysin 2) revealed that IRAP is present in oxytocinergic and in vasopressinergic neurons. In schizophrenia patients, the numerical density of IRAP-expressing neurons in the paraventricular and the suprachiasmatic nuclei is significantly reduced, which might be associated with the reduction in neurophysin-containing neurons in these nuclei in schizophrenia. The pathophysiological role of lowered hypothalamic IRAP expression in schizophrenia remains to be established.

Carbon M, Correll CU (2014) Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia. CNS Spectr Suppl 1:38–52. doi:10.1017/S1092852914000601

Shilling PD, Feifel D (2016) Potential of oxytocin in the treatment of schizophrenia. CNS Drugs 30:193–208. doi:10.1007/s40263-016-0315-x CrossRefPubMedPubMedCentral

Frank E, Landgraf R (2008) The vasopressin system–from antidiuresis to psychopathology. Eur Pharmacol 583:226–242. doi:10.1016/j.ejphar.2007.11.063 CrossRef

Rubin LH, Carter CS, Bishop JR, Pournajafi-Nazarloo H, Drogos LL, Hill SK, Ruocco AC, Keedy SK, Reilly JL, Keshavan MS, Pearlson GD, Tamminga CA, Gershon ES, Sweeney JA (2014) Reduced levels of vasopressin and reduced behavioral modulation of oxytocin in psychotic disorders. Schizophr Bull 40:1374–1384. doi:10.1093/schbul/sbu CrossRefPubMedPubMedCentral

Rich ME, Caldwell HK (2015) A role for oxytocin in the etiology and treatment of schizophrenia. Front Endocrinol 6(90):2015. doi:10.3389/fendo.2015.00090 (eCollection 2015)

Feifel D, Shilling PD, MacDonald K (2016) A review of oxytocin’s effects on the positive, negative, and cognitive domains of schizophrenia. Biol Psychiatry 79:222–233. doi:10.1016/j.biopsych.2015.07.025 CrossRefPubMed

Uhrig S, Hirth N, Broccoli L, von Wilmsdorff M, Bauer M, Sommer C, Zink M, Steiner J, Frodl T, Malchow B, Falkai P, Spanagel R, Hansson AC, Schmitt A (2016) Reduced oxytocin receptor gene expression and binding sites in different brain regions in schizophrenia: a post-mortem study. Schizophr Res. doi:10.1016/j.schres.2016.04.019 PubMed

Oya K, Matsuda Y, Matsunaga S, Kishi T, Iwata N (2016) Efficacy and safety of oxytocin augmentation therapy for schizophrenia: an updated systematic review and meta-analysis of randomized, placebo-controlled trials. Eur Arch Psychiatry Clin Neurosci 26:439–450. doi:10.1007/s00406-015-0634-9 CrossRef

Davis MC, Green MF, Lee J, Horan WP, Senturk D, Clarke AD, Marder SR (2014) Oxytocin-augmented social cognitive skills training in schizophrenia. Neuropsychopharmacology 39:2070–2077. doi:10.1038/npp.2014.68 CrossRefPubMedPubMedCentral

10.

Cacciotti-Saija C, Langdon R, Ward PB, Hickie IB, Scott EM, Naismith SL, Moore L, Alvares GA, Redoblado Hodge MA, Guastella AJ (2015) A double-blind randomized controlled trial of oxytocin nasal spray and social cognition training for young people with early psychosis. Schizophr Bull 4:483–493. doi:10.1093/schbul/sbu094 CrossRef

11.

Michalopoulou PG, Averbeck BB, Kalpakidou AK, Evans S, Bobin T, Kapur S, Shergill SS (2015) The effects of a single dose of oxytocin on working memory in schizophrenia. Schizophr Res 162:62–63. doi:10.1016/j.schres.2014.12.029 CrossRefPubMedPubMedCentral

12.

Diwakarla S, Nylander E, Grönbladh A, Vanga SR, Khan YS, Gutiérrez-de-Terán H, Ng L, Pham V, Sävmarker J, Lundbäck T, Jenmalm-Jensen A, Andersson H, Engen K, Rosenström U, Larhed M, Åqvist J, Chai SY, Hallberg M (2016) Binding to and inhibition of insulin-regulated aminopeptidase by macrocyclic disulfides enhances spine density. Mol Pharmacol 89:413–424. doi:10.1124/mol.115.102533 CrossRefPubMed

13.

Souza RP, Ismail P, Meltzer HY, Kennedy JL (2010) Variants in the oxytocin gene and risk for schizophrenia. Schizophr Res 121(1–3):279–280. doi:10.1016/j.schres.2010.04.019 CrossRefPubMed

14.

Ebstein RP, Knafo AP, Mankuta D, Chew SH, Lai PS (2012) The contributions of oxytocin and vasopressin pathway genes to human behavior. Horm Behav 61:359–379. doi:10.1016/j.yhbeh.2011.12.014 CrossRefPubMed

15.

Teltsh O, Kanyas-Sarner K, Rigbi A, Greenbaum L, Lerer B, Kohn Y (2012) Oxytocin and vasopressin genes are significantly associated with schizophrenia in a large Arab-Israeli pedigree. Int J Neuropsychopharmacol 15:309–319. doi:10.1017/S1461145711001374 CrossRefPubMed

16.

Chen FS, Kumsta R, Dvorak F, Domes G, Yim OS, Ebstein RP, Heinrichs M (2015) Genetic modulation of oxytocin sensitivity: a pharmacogenetic approach. Transl Psychiatry 5:e664. doi:10.1038/tp.2015.163 CrossRefPubMedPubMedCentral

17.

Goldman M, Marlow-O’Connor M, Torres I, Carter CS (2008) Diminished plasma oxytocin in schizophrenic patients with neuroendocrine dysfunction and emotional deficits. Schizophr Res 98:247–255CrossRefPubMed

18.

Jobst A, Dehning S, Ruf S, Notz T, Buchheim A, Henning-Fast K, Meißner D, Meyer S, Bondy B, Müller N, Zill P (2014) Oxytocin and vasopressin levels are decreased in the plasma of male schizophrenia patients. Acta Neuropsychiatr 26:347–355. doi:10.1017/neu.2014.20 CrossRefPubMed

19.

Ryan MC, Sharifi N, Condren R, Thakore JH (2004) Evidence of basal pituitary–adrenal overactivity in first episode, drug naïve patients with schizophrenia. Psychoneuroendocrinology 29:1065–1070CrossRefPubMed

20.

Wied De, Sigling HO (2002) Neuropeptides involved in the pathophysiology of schizophrenia and major depression. Neurotox Res 4:453–468CrossRefPubMed

21.

Krishnamurthy D, Harris LW, Levin Y, Koutroukides TA, Rahmoune H, Pietsch S, Vanattou-Saifoudine N, Leweke FM, Guest PC, Bahn S (2013) Metabolic, hormonal and stress-related molecular changes in post-mortem pituitary glands from schizophrenia subjects. World J Biol Psychiatry 14:478–489. doi:10.3109/15622975.2011.601759 CrossRefPubMed

22.

Frederiksen SO, Ekman R, Gottfries CG, Widerlov E, Jonsson S (1991) Reduced concentrations of galanin, arginine vasopressin, neuropeptide Y and peptide YY in the temporal cortex but not in the hypothalamus of brains from schizophrenics. Acta Psychiatr Scand 83:273–277CrossRefPubMed

23.

Mai JK, Berger K, Sofroniew MV (1993) Morphometric evaluation of neurophysin-immunoreactivity in the human brain: pronounced inter-individual variability and evidence for altered staining patterns in schizophrenia. J Hirnforsch 34:133–154PubMed

24.

Wallis MG, Lankford MF, Keller SR (2007) Vasopressin is a physiological substrate for the insulin-regulated aminopeptidase IRAP. Am J Physiol Endocrinol Metab 293:E1092–E1102CrossRefPubMed

25.

Nakada TA, Russell JA, Wellman H, Boyd JH, Nakada E, Thain KR, Thair SA, Hirasawa H, Oda S, Walley KR (2011) Leucyl/cystinyl aminopeptidase gene variants in septic shock. Chest 139:1042–1049CrossRefPubMed

26.

Carrera-González MP, Ramírez-Expósito MJ, de Saavedra JM, Sánchez-Agesta R, Mayas MD, Martínez-Martos JM (2011) Hypothalamus–pituitary–thyroid axis disruption in rats with breast cancer is related to an altered endogenous oxytocin/insulin-regulated aminopeptidase (IRAP) system. Tumour Biol 32:543–549. doi:10.1007/s13277-010-0149-y CrossRefPubMed

27.

Loyens E, De Bundel D, Demaegdt H, Chai SY, Vanderheyden P, Michotte Y, Gard P, Smolders I (2013) Antidepressant-like effects of oxytocin in mice are dependent on the presence of insulin-regulated aminopeptidase. Int J Neuropsychopharmacol 16:1153–1163. doi:10.1017/S1461145712001149 CrossRefPubMed

28.

Bauer K (2004) Cystinyl aminopeptidase, oxytocinase and insulin-regulated aminopeptidase. In: Barret AJ, Rawlings ND, Woessner JF (eds) Handbook of proteolytic enzymes, 2nd edn. Elsevier Academic Press, London, pp 307–313

29.

Fernández-Atucha A, Echevarría E, Larrinaga G, Gil J, Martínez-Cengotitabengoa M, González-Pinto AM, Irazusta J, Seco J (2015) Plasma peptidases as prognostic biomarkers in patients with first-episode psychosis. Psychiatry Res 228(2):197–202. doi:10.1016/j.psychres.2015.04.027 CrossRefPubMed

30.

Prieto I, Villarejo AB, Segarra AB, Wangensteen R, Banegas I, de Gasparo M, Vanderheyden P, Zorad S, Vives F, Ramírez-Sánchez M (2015) Tissue distribution of CysAP activity and its relationship to blood pressure and water balance. Life Sci 134:73–78. doi:10.1016/j.lfs.2015.04.023 CrossRefPubMed

31.

Chissoe S, Ehm MG, Jean St. P (2008) Genes associated with schizophrenia. US Patent Appl 20080176239; p 80

32.

Sanders AR, Göring HH, Duan J, Drigalenko EI, Moy W, Freda J, He D, Shi JMGS, Gejman PV (2013) Transcriptome study of differential expression in schizophrenia. Hum Mol Genet 22:5001–50014. doi:10.1093/hmg/ddt350 CrossRefPubMedPubMedCentral

33.

Chai SY, Fernando R, Ye S, Peck GR, Albiston AL (2012) Insulin-regulated aminopeptidase. In: Hopper N, Lendeckel U (eds) Aminopeptidases in biology and disease. Springer, New York, pp 61–82

34.

LaCrosse AL, Olive MF (2013) Neuropeptide systems and schizophrenia. CNS Neurol Disord Drug Targets 12(5):619–632CrossRefPubMed

35.

Stragier B, Demaegdt H, De Bundel D, Smolders I, Sarre S, Vauquelin G, Ebinger G, Michotte Y, Vanderheyden P (2007) Involvement of insulin-regulated aminopeptidase and/or aminopeptidase N in the angiotensin IV-induced effect on dopamine release in the striatum of the rat. Brain Res 1131:97–105CrossRefPubMed

36.

Cachope R, Cheer JF (2014) Local control of striatal dopamine release. Front Behav Neurosci 8:188. doi:10.3389/fnbeh.2014.00188 (eCollection 2014) CrossRefPubMedPubMedCentral

37.

Saveanu L, van Endert P (2012) The role of insulin-regulated aminopeptidase in MHC class I antigen presentation. Front Immunol 21(3):57. doi:10.3389/fimmu.2012.00057 (eCollection 2012)

38.

McAllister AK (2014) Major histocompatibility complex I in brain development and schizophrenia. Biol Psychiatry 75:262–268. doi:10.1016/j.biopsych.2013.10.003 CrossRefPubMed

39.

Fernando RN, Albiston AL, Chai SY (2008) The insulin-regulated aminopeptidase IRAP is colocalised with GLUT4 in the mouse hippocampus–potential role in modulation of glucose uptake in neurones? Eur J Neurosci 28:588–598. doi:10.1111/j.1460-9568.2008.06347.x CrossRefPubMed

40.

Hazlett EA, Buchsbaum MS, Haznedar MM, Singer MB, Germans MK, Schnur DB, Jimenez EA, Buchsbaum BR, Troyer BT (1998) Prefrontal cortex glucose metabolism and startle eyeblink modification abnormalities in unmedicated schizophrenia patients. Psychophysiology 35:186–198CrossRefPubMed

41.

Chai SY, Bastias MA, Clune EF, Matsacos DJ, Mustafa T, Lee JH, McDowall SG, Paxinos G, Mendelsohn FA, Albiston AL (2000) Distribution of angiotensin IV binding sites (AT4 receptor) in the human forebrain, midbrain and pons as visualised by in vitro receptor autoradiography. J Chem Neuroanat 20:339–348CrossRefPubMed

42.

Albiston AL, McDowall SG, Matsacos D, Sim P, Clune E, Mustafa T, Lee J, Mendelsohn FA, Simpson RJ, Connolly LM, Chai SY (2001) Evidence that the angiotensin IV (AT(4)) receptor is the enzyme insulin-regulated aminopeptidase. J Biol Chem 276:48623–48626CrossRefPubMed

43.

Albiston AL, Fernando RN, Yeatman HR, Burns P, Ng L, Daswani D, Diwakarla S, Pham V, Chai SY (2010) Gene knockout of insulin-regulated aminopeptidase: loss of the specific binding site for angiotensin IV and age-related deficit in spatial memory. Neurobiol Learn Mem 93:19–30. doi:10.1016/j.nlm.2009.07.011 CrossRefPubMed

44.

Andersson H, Hallberg M (2012) Discovery of inhibitors of insulin-regulated aminopeptidase as cognitive enhancers. Int J Hypertens 2012:789671. doi:10.1155/2012/789671 CrossRefPubMedPubMedCentral

45.

Bohlen Von, Halbach O (2003) Angiotensin IV in the central nervous system. Cell Tissue Res 311:1–9CrossRef

46.

Fernando RN, Larm J, Albiston AL, Chai SY (2005) Distribution and cellular localization of insulin-regulated aminopeptidase in the rat central nervous system. J Comp Neurol 487:372–390CrossRefPubMed

47.

Tobin VA, Arechaga G, Brunton PJ, Russell JA, Leng G, Ludwig M, Douglas AJ (2014) Oxytocinase in the female rat hypothalamus: a novel mechanism controlling oxytocin neurones during lactation. J Neuroendocrinol 26:205–216. doi:10.1111/jne.12141 CrossRefPubMed

48.

Müller S, Lendeckel U, Dobrowolny H, Steiner J, Bogerts B, Bernstein HG (2013) Some notes on insulin-regulated aminopeptidase in depression. Int J Neuropsychopharmacol 16:1877–1878. doi:10.1017/S1461145713000199 CrossRefPubMed

49.

Bernstein HG, Lendeckel U, Dobrowolny H, Stauch R, Steiner J, Grecksch G, Becker A, Jirikowski GF, Bogerts B (2008) Beacon-like/ubiquitin-5-like immunoreactivity is highly expressed in human hypothalamus and increased in haloperidol-treated schizophrenics and a rat model of schizophrenia. Psychoneuroendocrinology. 33:340–351. doi:10.1016/j.psyneuen.2007.12.002 CrossRefPubMed

50.

Bernstein HG, Stanarius A, Baumann B, Henning H, Krell D, Danos P, Falkai P, Bogerts B (1998) Nitric oxide synthase-containing neurons in the human hypothalamus: reduced number of immunoreactive cells in the paraventricular nucleus of depressive patients and schizophrenics. Neuroscience 83:867–875CrossRefPubMed

51.

Mai JK, Paxinos G, Assheuer JK (2003) Atlas of the human brain. Elsevier Academic Press, Amsterdam

52.

Bernstein HG, Meyer-Lotz G, Dobrowolny H, Bannier J, Steiner J, Walter M, Bogerts B (2015) Reduced density of glutamine synthetase immunoreactive astrocytes in different cortical areas in major depression but not in bipolar I disorder. Front Cell Neurosci 9:273. doi:10.3389/fncel.2015.00273 (eCollection 2015) CrossRefPubMedPubMedCentral

53.

Bernstein HG, Heinemann A, Krell D, Dobrowolny H, Bielau H, Keilhoff G, Bogerts B (2005) Hypothalamic nitric oxide synthase in affective disorder: focus on the suprachiasmatic nucleus. Cell Mol Biol 51:279–284PubMed

54.

Gerendai I, Halász B (1997) Neuroendocrine asymmetry. Front Neuroendocrinol 18:354–381CrossRefPubMed

55.

Bernstein HG, Bannier J, Meyer-Lotz G, Steiner J, Keilhoff G, Dobrowolny H, Walter M, Bogerts B (2014) Distribution of immunoreactive glutamine synthetase in the adult human and mouse brain. Qualitative and quantitative observations with special emphasis on extra-astroglial protein localization. J Chem Neuroanat 61–62:33–50. doi:10.1016/j.jchemneu.2014.07.003 CrossRefPubMed

56.

Toda S, Ando H, Nagasaka T, Tsukahara S, Nomura M, Kotani Y, Nomura S, Kikkawa F, Tsujimoto M, Mizutani S (2002) Existence of placental leucine aminopeptidase/oxytocinase/insulin-regulated membrane aminopeptidase in human endometrial epithelial cells. J Clin Endocrinol Metab 87:1384–1389CrossRefPubMed

57.

Bernstein HG, Keilhoff G, Steiner J, Dobrowolny H, Bogerts B (2010) The hypothalamus in schizophrenia research: no longer a wallflower existence. Open Neuroendocrinol J 3:59–67CrossRef

58.

Malidelis YI, Panayotacopoulou MT, van Heerikhuize JJ, Unme-Hopa U, Kontostavlaki DP, Swaab DF (2005) Absence of a difference in the neurosecretory activity of supraoptic nucleus of vasopressin neurons of neuroleptic-treated schizophrenic patients. Neuroendocrinology 82:63–69CrossRefPubMed

59.

Purba JS, Hoogendijk WJ, Hofman MA, Swaab D (1996) Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. Arch Gen Psychiatry 53:137–143. doi:10.1001/archpsyc.1996.01830020055007 CrossRefPubMed

60.

Kasparek-Zymowska B, Zymowski Z, Biernacka K, Kucharska K, Rybakowski F (2016) Impaired social recognition in Asperger syndrome and anorexia nervosa. In search for endophenotypes of social cognition. Psychiatr Pol 50:533–542CrossRef

61.

Theofanopoulou C (2016) Implications of oxytocin in human linguistic cognition: from genome to phenome. Front Neurosci. doi:10.3389/fnins.2016.00271 PubMedPubMedCentral

62.

Almeida D (2015) Oxytocin: a neurohormone link to the epigenetics of early life adversity and suicide. Poster, RQSHA research day 2015, Quebec, Canada

63.

Japundžić-Žigon N (2013) Vasopressin and oxytocin in control of the cardiovascular system. Curr Neuropharmacol 11:218–230. doi:10.2174/1570159X11311020008 CrossRefPubMedPubMedCentral

64.

Shah JN, Qureshi SU, Jawaid A, Schulz PE (2012) Is there evidence for late cognitive decline in chronic schizophrenia? Psychiatr Q 83:127–144. doi:10.1007/s11126-011-9189-8 CrossRefPubMed

65.

Engelmann M, Ebner K, Landgraf R, Wotjak CT (2006) Effects of Morris water maze testing on the neuroendocrine stress response and intrahypothalamic release of vasopressin and oxytocin in the rat. Horm Behav 50:496–501CrossRefPubMed

66.

Van Asselen M, Kessels RP, Neggers SF, Kappelle LJ, Frijns CJ, Postma A (2006) Brain areas involved in spatial working memory. Neuropsychologia 44:1185–1194CrossRefPubMed

67.

Dai J, Swaab DF, Buijs JM (1997) Distribution of vasopressin and vasoactive intestinal polypeptide (VIP) fibers in the human hypothalamus with special emphasis on suprachiasmatic nucleus efferent projections. J Comp Neurol 383:397–414CrossRefPubMed

68.

Sivukhina EV, Morozov IuE, Dolzhikov AA, Jirikowski GF, Grinevich V (2010) Comparison of vasopressin and oxytocin expressions in the hypothalamo-neurohypophysial system of patients with chronic heart failure. Horm Metab Res 42:56–60. doi:10.1055/s-0029-1234081 CrossRefPubMed

69.

Trudel E, Bourque CW (2010) Central clock excites vasopressin neurons by waking osmosensory afferents during late sleep. Nat Neurosci 13:467–474. doi:10.1038/nn.2503 CrossRefPubMed

70.

Trbovic SN (2010) Schizophrenia as a possible dysfunction of the suprachiasmatic nucleus. Med Hypotheses 74:127–131. doi:10.1016/j.mehy.2009.07.019 CrossRefPubMed

71.

Keller SR (2004) Role of the insulin-regulated aminopeptidase IRAP in insulin action and diabetes. Biol Pharm Bull 27:761–764CrossRefPubMed

72.

Niwa M, Numaguchi Y, Ishii M, Kuwahata T, Kondo M, Shibata R, Miyata K, Oike Y, Murohara T (2015) IRAP deficiency attenuates diet-induced obesity in mice through increased energy expenditure. Biochem Biophys Res Commun 457:12–18. doi:10.1016/j.bbrc.2014.12.071 CrossRefPubMed

Titel: Insulin-regulated aminopeptidase immunoreactivity is abundantly present in human hypothalamus and posterior pituitary gland, with reduced expression in paraventricular and suprachiasmatic neurons in chronic schizophrenia
verfasst von: Hans-Gert Bernstein
Susan Müller
Hendrik Dobrowolny
Carmen Wolke
Uwe Lendeckel
Alicja Bukowska
Gerburg Keilhoff
Axel Becker
Kurt Trübner
Johann Steiner
Bernhard Bogerts
Publikationsdatum: 29.12.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: European Archives of Psychiatry and Clinical Neuroscience / Ausgabe 5/2017
Print ISSN: 0940-1334
Elektronische ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-016-0757-7

Neu im Fachgebiet Psychiatrie

18.04.2024 | Arterielle Hypertonie | Nachrichten

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Insulin-regulated aminopeptidase immunoreactivity is abundantly present in human hypothalamus and posterior pituitary gland, with reduced expression in paraventricular and suprachiasmatic neurons in chronic schizophrenia

Abstract

Neu im Fachgebiet Psychiatrie

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Delir kann Demenz begünstigen

Zunahme von Geschlechtsinkongruenz und -dysphorie registriert

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Update Psychiatrie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2017

Expressional profile of the diacylglycerol kinase eta gene DGKH

Abnormalities in the brain–immune system in psychotic disorders: from pathogenesis to prevention

Impaired monocyte activation in schizophrenia: ultrastructural abnormalities and increased IL-1β production

Intake of 7,8-dihydroxyflavone from pregnancy to weaning prevents cognitive deficits in adult offspring after maternal immune activation

Cerebrospinal fluid microglia and neurodegenerative markers in twins concordant and discordant for psychotic disorders

Chronic low-grade peripheral inflammation is associated with severe nicotine dependence in schizophrenia: results from the national multicentric FACE-SZ cohort

Neu im Fachgebiet Psychiatrie

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Delir kann Demenz begünstigen

Zunahme von Geschlechtsinkongruenz und -dysphorie registriert

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Update Psychiatrie